Objectives: This phase III trial asks whether third-line cabozantinib, a novel oral multi-targeted tyrosine kinase inhibitor, can improve pain and bone scan responses compared with mitoxantrone (Novantrone) plus prednisone.
Key entry or exclusion criteria: Patients must have received prior docetaxel (Taxotere) plus either abiraterone (Zytiga) or MDV3100 (enzalutamide) treatment, and bone metastases that require opioid narcotic intervention for pain.
Locations: 20 sites.
Goal: 246 patients.
Study sponsor: Exelixis
Link for more information: clinicaltrials.gov/ct2/show/NCT01522443
NIH clinical trials identifier: NCT01522443